ENDRA Life Sciences Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.94 million compared to USD 2.86 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 1.33 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2916 USD | +0.38% | -3.67% | -86.25% |
05-14 | Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.25% | 3.21M | |
+31.54% | 49.46B | |
+1.06% | 42.58B | |
+48.88% | 42.49B | |
-5.26% | 29.09B | |
+12.36% | 26.61B | |
-23.61% | 18.64B | |
+7.24% | 13.16B | |
+30.84% | 12.55B | |
+23.62% | 12.1B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023